Trial · NCT07332091
Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis
NCT07332091, Phase 2, Active not recruiting, CSL Behring
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis. Trials, record NCT07332091. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07332091
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis
- NCT number
- NCT07332091
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 84 participants, estimated
- Lead sponsor
- CSL Behring
- Conditions
- Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis
- Interventions
- Vamifeport, Placebo
- First posted
- 2026-01-12
- Last updated
- 2026-10-21
Source ClinicalTrials.gov
Registered outcomes28
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change from baseline in magnetic resonance imaging (MRI)-based liver iron concentration (LIC) | At Baseline and Day 360 | |
| Secondary | Number of participants with treatment-emergent adverse events (TEAEs) | Up to Day 390 | |
| Secondary | Percentage of participants with TEAEs | Up to Day 390 | |
| Secondary | Number of participants with treatment-emergent serious adverse events (SAEs) | Up to Day 390 | |
| Secondary | Percentage of participants with treatment-emergent SAEs | Up to Day 390 | |
| Secondary | Number of participants with clinically significant change from baseline in clinical safety laboratory tests and 12-lead electrocardiogram (ECG) | From Baseline to Day 390 | Clinical safety laboratory tests will include hematology, biochemistry and coagulation. |
| Secondary | Percentage of participants with clinically significant change from baseline in clinical safety laboratory tests and 12-lead ECG | From Baseline to Day 390 | Clinical safety laboratory tests will include hematology, biochemistry and coagulation. |
| Secondary | Change from baseline in transferrin saturation (TSAT) (measured at trough) | From Baseline to Day 360 | |
| Secondary | Number of participants with TSAT less than or equal to (<=) 45% (measured at trough) | From Baseline to Day 360 | |
| Secondary | Percentage of participants with TSAT <= 45% (measured at trough) | From Baseline to Day 360 |
1 to 10 of 28Source ClinicalTrials.gov
See all 28 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07332091
GET https://conductscience.org/api/trials/v1/NCT07332091/registered?page=2